Blood Volume Measurements Improved Survival

Prospective randomized control trial in Surgical ICU

N=100, 70% Septic Shock / Sepsis / ARDS

  66% reduction in mortality

  20% reduction in LOS

  36 hour earlier treatment decisions

  44% change in treatment strategy

“An important aspect of care was the earlier treatment of intravascular volume deviations in the BVA group, before the abnormality became clinically manifested.”

Mihae Yu, M.D. – Queens Hospital

66% reduction in mortality

44% change in treatment strategy

Blood Volume Measurements Improved Survival

Prospective randomized control in which 100 critically ill surgical patients with septic shock, sever sepsis, severe respiratory failure, and/or cardiovascular collapse were evaluated. Mean APACHE II scores were comparable across both study arms, at 25 (BVA=50) vs. 24 (conventional, n=50) (p=0.16). All patients underwent BVA testing; physicians were blinded to BVA results for the control group, which was conventionally managed by pulmonary artery catheter (PAC).

   Hypervolemia present in 48% control vs. 37% BVA

   RBC deficiency present in 33% control vs. 16% BVA

   Control group mean delay in transfusion of 1.5 ± 2 days

   PAC did not reliably correlate with volume

66% reduction in mortality

For the BVA group, 44% of test results led to a change in treatment strategy

“An important aspect of care was the earlier treatment of intravascular volume deviations in the BVA group, before the abnormality became clinically manifested.”

Mihae Yu, M.D. – Queens Hospital

Persistently Elevated Albumin Transudation Rate Associated With Higher Mortality

Rate at which the albumin transudates out of circulation shown to be predictive of ICU mortality in cohort with 70% respiratory failure.

Retrospective Study in Surgical ICU

N = 164


Civetta, Taylor, & Kirby’s Critical Care, Fourth Edition 2009

Partner With the Dedicated Leader in BVA

As the pioneer in blood volume analysis, Daxor provides education and the resources needed to ensure easy onboarding along with continuing support to drive maximum value from your BVA system throughout your facility. With a long-standing commitment to improving care and numerous studies validating our technology, Daxor is completely focused on advancing healthcare by enabling optimal fluid management with blood volume analysis. Our vision is optimal blood volume for all.

Volume is Vital. End the Debate With Daxor.

Call us at 865-425-0555.

 

Daxor Corporation is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for use in a broad range of medical and surgical conditions.

Daxor Corporation – 107 Meco Lane, Oak Ridge, TN 37830
Phone: 865-425-0555 | Fax: 516-828-4772
info@daxor.com | daxor.com

ISO 13485 Certified

Made in the USA.

COPYRIGHT 2021 © DAXOR CORPORATION – ALL RIGHTS RESERVED.